Papillary thyroid carcinoma tall cell variant

Thyroid

Volumn 18, Issue 11, 2008, Pages 1179-1181

  Ghossein, Ronald ^a   Livolsi, Virginia A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUORODEOXYGLUCOSE; MATRIX METALLOPROTEINASE; MUCIN 1; RADIOACTIVE IODINE;

ADULT; ARTICLE; B RAF GENE; CANCER PATIENT; CANCER RECURRENCE; CYTOPLASM; EOSINOPHIL; GENE MUTATION; HUMAN; ONCOGENE; PAPILLARY THYROID CARCINOMA TALL CELL VARIANT; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

CARCINOMA, PAPILLARY; CELL NUCLEUS; CELL SHAPE; CYTOPLASM; EOSINOPHILIA; HUMANS; IODINE RADIOISOTOPES; MUTATION; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 56549084556     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0164     Document Type: Article

References (21)

1. Chan JK 2000 Tumors of the thyroid and parathyroid glands. Part A. The thyroid gland. In: Fletcher CDM (ed) Diagnostic Histopathology of Tumors, Second edition, volume 2. Churchill-Livingstone, London, pp 959-1038.
2. Hawk WA, Hazard JB 1976 The many appearances of papillary carcinoma of the thyroid. Clevel Clin Q 43:207-215.
3. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC 1988 Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12:22-27.
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004. Pathology and genetics of tumours of endocrine organs. World Health Organization Classification of Tumours IARC Press, Lyon.
5. Rosai J, Carcangiu, ML, DeLellis RA 1992 Tumors of the thyroid gland. In: Rosai J, Sobin CH (eds) Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, DC, pp 161-182.
6. Sobrinho-Simoes MA, Nesland JM, Holm R, Sambade MC, Johannessen JV 1985 Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 8:131-142.
7. Akslen LA, LiVolsi VA 2000 Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88:1902-1908.
8. Ghossein R, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B, Tuttle RM 2007 Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 17:655-661.
9. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA 2006 Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286-1295.
10. Michels JJ, ScI MJ, Henry-Amar M, Bardet S 2007 Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 38:212-219.
11. Ruter A, Nishiyama R, Lennquist S 1997 Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 21:15-20.
12. Ostrowski ML, Merino MJ 1996 Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964-974.
13. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B 2004 Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780-3789.
14. Wesseling J, van der Valk SW, Hilkens J 1996 A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin = MUC1. Mol Biol Cell 7:565-577.
15. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J 1995 Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265.
16. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W 1992 Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23:1395-1401.
17. Adeniran AJ, Zhu Z, Gandhi M, Steward D, Fidler JP, Giordano T, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222.
18. Rivera M, Ghossein R, Schoder H, Gomez D, Larson SM, Tuttle RM 2008 Histopathologic characterization of radioactive iodine refractory thyroid carcinomas FDG-PET positive thyroid carcinoma. Cancer 113:48-56.
19. Xing M, Westra W, Tufano RP, Cohen Y, Rosenbaum E, Thoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Bosaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
20. Groussin L, Fagin JA 2006 Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab 2:180-181.
21. Tuttle RM 2008 Personal communication, April.